| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer
|
Liu, Zhaopei
|
|
|
171 |
C |
p. 133-142
|
artikel
|
| 2 |
Bilateral diffuse uveal melanocytic proliferation (BDUMP) as ocular toxicity from durvalumab in advanced renal carcinoma
|
Mihic Góngora, Luka
|
|
|
171 |
C |
p. 10-12
|
artikel
|
| 3 |
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study
|
Conforti, Fabio
|
|
|
171 |
C |
p. 183-192
|
artikel
|
| 4 |
Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients
|
Haeusler, Gabrielle M.
|
|
|
171 |
C |
p. 1-9
|
artikel
|
| 5 |
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis
|
Pesenti, Chiara
|
|
|
171 |
C |
p. 85-95
|
artikel
|
| 6 |
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer
|
Bryant, Alex K.
|
|
|
171 |
C |
p. 55-63
|
artikel
|
| 7 |
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
|
Gauci, Marie-Léa
|
|
|
171 |
C |
p. 203-231
|
artikel
|
| 8 |
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study
|
Even, Caroline
|
|
|
171 |
C |
p. 259-268
|
artikel
|
| 9 |
Events prediction after treatment in HPV-driven oropharyngeal carcinoma using machine learning
|
Dinia, Adil
|
|
|
171 |
C |
p. 106-113
|
artikel
|
| 10 |
Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT)
|
Ternov, Klara K.
|
|
|
171 |
C |
p. 75-84
|
artikel
|
| 11 |
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma
|
Rimini, Margherita
|
|
|
171 |
C |
p. 232-241
|
artikel
|
| 12 |
Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
|
Corti, Chiara
|
|
|
171 |
C |
p. 25-42
|
artikel
|
| 13 |
Letter re: Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis
|
Kawada, Tomoyuki
|
|
|
171 |
C |
p. 280-281
|
artikel
|
| 14 |
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
|
Graham, Jeffrey
|
|
|
171 |
C |
p. 124-132
|
artikel
|
| 15 |
Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials
|
Espenel, Sophie
|
|
|
171 |
C |
p. 242-258
|
artikel
|
| 16 |
Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial
|
Zhang, Junsheng
|
|
|
171 |
C |
p. 150-160
|
artikel
|
| 17 |
Re: Market access to new anticancer medicines for children and adolescents with cancer in Europe
|
Michalowski, Mariana B.
|
|
|
171 |
C |
p. 22-24
|
artikel
|
| 18 |
Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
|
Altundag, Kadri
|
|
|
171 |
C |
p. 43
|
artikel
|
| 19 |
Response to the letter entitled: Re: ‘Prognostic value of high-risk HPV DNA and p16INK4a immunohistochemistry in anal cancer patients: An individual patient data meta-analysis’
|
Obermueller, Theresa
|
|
|
171 |
C |
p. 282-283
|
artikel
|
| 20 |
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)
|
Ozaki, Yukinori
|
|
|
171 |
C |
p. 193-202
|
artikel
|
| 21 |
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
|
Di Giacomo, Anna M.
|
|
|
171 |
C |
p. 143-149
|
artikel
|
| 22 |
Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands
|
Heimovaara, Joosje H.
|
|
|
171 |
C |
p. 13-21
|
artikel
|
| 23 |
The MUSES∗: a prognostic study on 1360 patients with sinonasal cancer undergoing endoscopic surgery-based treatment
|
Ferrari, Marco
|
|
|
171 |
C |
p. 161-182
|
artikel
|
| 24 |
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
|
van Berge Henegouwen, J.M.
|
|
|
171 |
C |
p. 114-123
|
artikel
|
| 25 |
Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017
|
Baum, Philip
|
|
|
171 |
C |
p. 269-279
|
artikel
|
| 26 |
Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy
|
Mallet, Marion
|
|
|
171 |
C |
p. 96-105
|
artikel
|
| 27 |
Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients
|
Cui, Wanyuan
|
|
|
171 |
C |
p. 44-54
|
artikel
|
| 28 |
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer
|
Pinato, David J.
|
|
|
171 |
C |
p. 64-74
|
artikel
|
Tijdschrift beschrijving